KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Investments (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Long-Term Investments data on record, last reported at $10.3 billion in Q4 2025.

  • For Q4 2025, Long-Term Investments rose 15.29% year-over-year to $10.3 billion; the TTM value through Dec 2025 reached $10.3 billion, up 15.29%, while the annual FY2025 figure was $10.3 billion, 15.29% up from the prior year.
  • Long-Term Investments reached $10.3 billion in Q4 2025 per REGN's latest filing, roughly flat from $10.3 billion in the prior quarter.
  • Across five years, Long-Term Investments topped out at $10.3 billion in Q3 2025 and bottomed at $3.5 billion in Q1 2021.
  • Average Long-Term Investments over 5 years is $7.1 billion, with a median of $6.6 billion recorded in 2022.
  • Peak YoY movement for Long-Term Investments: skyrocketed 99.9% in 2022, then dropped 18.13% in 2023.
  • A 5-year view of Long-Term Investments shows it stood at $5.6 billion in 2021, then grew by 17.06% to $6.6 billion in 2022, then dropped by 18.13% to $5.4 billion in 2023, then soared by 64.92% to $8.9 billion in 2024, then grew by 15.29% to $10.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $10.3 billion in Q4 2025, $10.3 billion in Q3 2025, and $10.1 billion in Q2 2025.